GlaxoSmithKline (GSK) has formed a partnership with three NGOs as part of its commitment to reinvest 20% of profits made in the Least Developed Countries (LDCs) back into projects that strengthen the healthcare infrastructure in those countries. It has selected AMREF in East and Southern Africa, CARE International UK in Asia Pacific, and Save the Children in West Africa.
The objective of the partnerships is to improve health outcomes by supporting frontline health workers operating in these countries. It chose the charities for their expertise in accessing and supporting healthcare workers operating in these challenging rural and marginalised communities.
GSK currently supplies medicines to 37 of the 48 LDCs and 2010 profits available for reinvestment in 2011 amount to approximately £3.5 million. The amount available for investment in each country will be proportional to the amount of profit generated there. As the profits vary from country to country, GSK has set a minimum investment of £10,000.
Andrew Witty, CEO of GSK said: "Although the profits we make in LDCs are relatively small at this time, our commitment to reinvest 20% of them provides a sustainable model to help improve healthcare infrastructure – one of the key health challenges in these countries".